Eliyahu Sharon Kalif Sells 153,251 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Eliyahu Sharon Kalif sold 153,251 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the completion of the transaction, the executive vice president owned 172,184 shares in the company, valued at $6,131,472.24. The trade was a 47.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Eliyahu Sharon Kalif also recently made the following trade(s):

• On Thursday, February 26th, Eliyahu Sharon Kalif sold 345,810 shares of Teva Pharmaceutical Industries stock. The stock was sold at an average price of $33.64, for a total transaction of $11,633,048.40.

Teva Pharmaceutical Industries Trading Up 0.7%

NYSE:TEVA opened at $34.32 on Thursday. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of $39.46 billion, a PE ratio of 25.80, a price-to-earnings-growth ratio of 3.29 and a beta of 0.86. The firm’s 50 day moving average is $31.70 and its 200 day moving average is $30.80. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.99 and a 12 month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The business had revenue of $3.98 billion for the quarter. Sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several research reports. Truist Financial upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Scotiabank upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Piper Sandler reiterated an “overweight” rating and issued a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $41.78.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors have recently modified their holdings of the company. Aster Capital Management DIFC Ltd bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $25,000. Cornerstone Planning Group LLC increased its position in shares of Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after acquiring an additional 755 shares in the last quarter. Allworth Financial LP increased its position in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust increased its position in shares of Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.